Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1317-1320

  Barchiesi, Francesco ^a,b   Najvar, Laura K ^a   Luther, Michael F ^c   Scalise, Giorgio ^b   Rinaldi, Michael G ^a,c   Graybill, John R ^a,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

AIDS RELATED COMPLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0029865331     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1317     Document Type: Article

References (30)

1. Barchiesi, F., R. J. Hollis, M. Del Poeta, D. A. McGough, G. Scalise, M. G. Rinaldi, and M. A. Pfaller. 1995 Transmission of fluconazole-resistant Candida albicans between patients with AIDS and oropharyngeal candidiasis documented by pulsed field gel electrophoresis. Clin. Infect. Dis. 21:561-564.
2. Barchiesi, F., R. J. Hollis, D. A. McGough, G. Scalise, M. G. Rinaldi, and M. A. Pfaller. 1995. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin. Infect. Dis. 20:634-640.
3. Bart-Dellabesse, E., P. Boiron, A. Carlotti, and B. Dupont. 1993. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J. Clin. Microbiol. 31:2933-2937.
4. Boken, D. J., S. Swindells, and M. G. Rinaldi. 1993. Fluconazole-resistant Candida albicans. Clin. Infect. Dis. 17:1018-1021.
5. Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. 1993. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob. Agents Chemother 37: 2449-2453.
6. Garcia-Hermoso, D., F. Dromer, L. Improvisi, F. Provost, and B. Dupont. 1995. Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole. Antimicrob. Agents Chemother. 39:656-660.
7. Goff, D. A., S. L. Koletar, W. J. Bueshing, J. Barnishan, and R. J. Fass. 1995. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azole. Clin. Infect. Dis. 20:77-83.
8. He, X., R. N. Tiballi, L. T. Zarins, S. F. Bradley, J. A. Sangeorzan, and C. A. Kauffman. 1994. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:2494-2497.
9. Hennequin, C., M. Labenne, M. Benkerrou, and M. Hambourg. 1994. Fluconazole-resistant Candida albicans in immunocompetent child. Clin Infect. Dis. 19:1179-1180.
10. Imam, N., C. C. J. Carpenter, K. H. Mayer, A. Fisher, M. Stein, and S. B. Danforth. 1990. Hierarchial pattern of mucosal Candida infection in HIV-seropositive woman Am. J Med. 89:142-146.
11. Johnson, E. M., D. W. Warnock, J. Luker, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J. Antimicrob. Chemother. 35:103-114.
12. Klein, R. S., C. A. Harris, C. B. Small, B. Moll, M. Lesser, and G. H. Friedland. 1984. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immune deficiency syndrome. N. Engl. J. Med. 311: 354-358.
13. Kwon-Chung, K. J., and J. E. Bennett. 1992. Candidiasis. p. 280-336. In K. J Kwon-Chung and J. E Bennett (ed.), Medical mycology. Lea & Febiger, Philadelphia.
14. Lyman, C. A., and T. J. Walsh. 1992. Systematically administered antifungal agents. A review of their clinical pharmacology and therapeutic application. Drugs 44:9-35.
15. Millon, L., A. Manteaux, G. Reboux, C. Drobacheff, M. Monud, T. Barale, and Y. Michel-Briand. 1994. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J. Clin. Microbiol. 32:1115-1118.
16. Odds, F. C. 1988. Pathogenesis of candidosis, p. 252-278. In F. C. Odds Candida and candidosis: a review and bibliography, 2nd ed. Baillière Tindall, London.
17. Odds, F. C. 1993. Resistance of yeasts to azole-derivative antifungal. J. Antimicrob. Chemother. 31:463-471.
18. Pfaller, M. A., J. Rhine-Chalberg, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among clinical isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
19. Powderly, W. G., K. Robinson, and E. J. Keath. 1993. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. J. Infect. Dis. 168:463-466.
20. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation of in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
21. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother 39:1-8.
22. Reynes, J., M. Mallie, P. Ravisse, and J.-M. Bastide. 1992. Activity of fluconazole against Candida albicans isolates from HIV+ patients in a digestive candidosis turkey model. J Med. Vet. Mycol. 30:363-367.
23. Rodríguez-Tudela, J. L., J. V. Martínez-Suárez, F. Dronda, F. Laguna, F. Chaves, and E. Valencia, 1995. Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. J. Antimicrob. Chemother. 35:793-804.
24. Ruhnke, M., A. Eigler, I. Tennagen, B. Geiseler, E. Engelmann, and M. Trautmann. 1994. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:2092-2098.
25. Ryley, J. F., R. G. Wilson, and K. J. Barrett-Bee. 1984. Azole resistance in Candida albicans J. Med Vet. Mycol 22:53-63.
26. Sandven, P., A. Biømeklett, A. Maeland, and the Norwegian Yeast Study Group. 1993. Susceptibility testing of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob. Agents Chemother. 37: 2443-2448.
27. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tihalli, and C. A. Kauffman. 1994. Epidemiology of oral candidiasis in HIV infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:3339-3346.
28. Smith, K. J., D. W. Warnock, C. T. Kennedy, E. M. Johnson, V. Hopwood, J. Van Custem, and H. Vanden Bossche. 1986. Azole resistance in Candida albicans. J. Med. Vet. Mycol. 24:133-144.
29. Troillet, N., C. Durussel, J. Bille, M. P. Glauser, and J. P. Chave. 1993. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur. J. Clin. Microbiol. Infect Dis. 12:911-915.
30. Velez, J. D., R. Allendoerfer, M. Luther, M. G. Rinaldi, and J. R. Graybill. 1993 Correlation azole susceptibility with in vivo response in a rnurine model of cryptococcal meningitis. J. Infect. Dis. 168:508-510.